products

Oxabact™:

is an oral product consisting of lyophilized live Oxalobacter formigenes cells, which is an oxalate-degrading bacterium isolated from human gut formulated in enteric-coated capsules. This bacterium can regulate both the dietary and endogenous components of the systemic oxalate in humans. The product supports long-term perpetual degradation of oxalate in lower GI-tract and promotes removal of endogenously produced systemic oxalate through enteric elimination. Pilot Phase I/II studies have shown promising results with significant plasma and urinary oxalate reduction in PH patients.

Oxazyme™:

is a non-systemic orally delivered formulation consisting of recombinant oxalate degrading enzyme. It is formulated to enzymatically degrade all the available dietary oxalate prior to its absorption, starting in the stomach. It is designed as a dietary intercept therapeutic for enteric and absorptive hyperoxalurias causing recurrent stone disease. The objective with Oxazyme™ is to bring the patients back to normal urinary oxalate levels.